• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

β-羟基丁酸重现了生酮代谢疗法在多囊肾病中的有益作用。

β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease.

作者信息

Torres Jacob A, Holznecht Nickolas, Asplund David A, Kroes Bradley C, Amarlkhagva Tselmeg, Haeffner Matthias M, Sharpe Elizabeth H, Koestner Stella, Strubl Sebastian, Schimmel Margaret F, Kruger Samantha, Agrawal Shagun, Aceves Brina A, Thangaraju Muthusamy, Weimbs Thomas

机构信息

Department of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.

Department of Biochemistry and Molecular Biology, University of Augusta, Augusta, GA, USA.

出版信息

iScience. 2024 Aug 20;27(9):110773. doi: 10.1016/j.isci.2024.110773. eCollection 2024 Sep 20.

DOI:10.1016/j.isci.2024.110773
PMID:39314240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11418134/
Abstract

Autosomal-dominant polycystic kidney disease (ADPKD) is a common monogenic disease characterized by the formation of fluid-filled renal cysts, loss of mitochondrial function, decreased fatty acid oxidation, increased glycolysis, and likely renal failure. We previously demonstrated that inducing a state of ketosis ameliorates or reverses PKD progression in multiple animal models. In this study, we compare time-restricted feeding and 48-h periodic fasting regimens in both juvenile and adult Cy/+ rats. Both fasting regimens potently prevent juvenile disease progression and partially reverse PKD in adults. To explore the mechanism of fasting, we administered β-hydroxybutyrate (BHB) to Cy/+ rats and orthologous mouse models of PKD ( , ). BHB recapitulated the effects of fasting in these models independent of stereoisomer, suggesting the effects of BHB are largely due to its signaling functions. These findings implicate the use of ketogenic metabolic therapy and BHB supplementation as potential disease modifiers of PKD and point toward underlying mechanisms.

摘要

常染色体显性多囊肾病(ADPKD)是一种常见的单基因疾病,其特征是形成充满液体的肾囊肿、线粒体功能丧失、脂肪酸氧化减少、糖酵解增加,并可能导致肾衰竭。我们之前证明,在多种动物模型中,诱导酮症状态可改善或逆转多囊肾病的进展。在本研究中,我们比较了幼年和成年Cy/+大鼠的限时进食和48小时周期性禁食方案。两种禁食方案都能有效预防幼年疾病进展,并部分逆转成年大鼠的多囊肾病。为了探究禁食的机制,我们给Cy/+大鼠和多囊肾病的直系同源小鼠模型施用了β-羟基丁酸(BHB)。BHB在这些模型中重现了禁食的效果,且与立体异构体无关,这表明BHB的作用很大程度上归因于其信号传导功能。这些发现表明,生酮代谢疗法和补充BHB可作为多囊肾病的潜在疾病修饰剂,并指向其潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/b4d2db2ceb28/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/baf419e04df6/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/da23a50674b7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/7bc1fbd4885a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/e68425a129e5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/f3c7c3e31ab7/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/49c9f64a462a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/f6b0df7f1aed/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/6e6d887e1e35/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/b4d2db2ceb28/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/baf419e04df6/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/da23a50674b7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/7bc1fbd4885a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/e68425a129e5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/f3c7c3e31ab7/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/49c9f64a462a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/f6b0df7f1aed/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/6e6d887e1e35/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e512/11418134/b4d2db2ceb28/gr8.jpg

相似文献

1
β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease.β-羟基丁酸重现了生酮代谢疗法在多囊肾病中的有益作用。
iScience. 2024 Aug 20;27(9):110773. doi: 10.1016/j.isci.2024.110773. eCollection 2024 Sep 20.
2
A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease.β-羟丁酸和柠檬酸的联合使用可改善多囊肾病大鼠模型的疾病进展。
Am J Physiol Renal Physiol. 2024 Mar 1;326(3):F352-F368. doi: 10.1152/ajprenal.00205.2023. Epub 2023 Dec 14.
3
Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.酮症可改善多囊肾病中的肾囊肿生长。
Cell Metab. 2019 Dec 3;30(6):1007-1023.e5. doi: 10.1016/j.cmet.2019.09.012. Epub 2019 Oct 17.
4
RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease.RESET-PKD 研究:常染色体显性遗传多囊肾病中短期生酮干预的初步试验
Nephrol Dial Transplant. 2023 Jun 30;38(7):1623-1635. doi: 10.1093/ndt/gfac311.
5
Ketogenic Interventions in Autosomal Dominant Polycystic Kidney Disease: A Comprehensive Review of Current Evidence.酮症干预治疗常染色体显性遗传多囊肾病:当前证据的综合评价。
Nutrients. 2024 Aug 13;16(16):2676. doi: 10.3390/nu16162676.
6
Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.二甲双胍改善常染色体显性遗传性多囊肾病小鼠模型的相关疾病参数。
Am J Physiol Renal Physiol. 2022 Jan 1;322(1):F27-F41. doi: 10.1152/ajprenal.00298.2021. Epub 2021 Nov 22.
7
Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.多囊肾病同源模型中缓慢发展的代谢重编程。
Am J Physiol Renal Physiol. 2022 Mar 1;322(3):F258-F267. doi: 10.1152/ajprenal.00262.2021. Epub 2022 Jan 17.
8
Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants.多囊肾病小鼠模型中的代谢紊乱可通过靶向线粒体的抗氧化剂得到改善。
Commun Biol. 2021 Oct 20;4(1):1200. doi: 10.1038/s42003-021-02730-w.
9
Potential Add-On Benefits of Dietary Intervention in the Treatment of Autosomal Dominant Polycystic Kidney Disease.饮食干预治疗常染色体显性遗传性多囊肾病的潜在附加益处。
Nutrients. 2024 Aug 6;16(16):2582. doi: 10.3390/nu16162582.
10
The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.酪氨酸激酶抑制剂尼达尼布可改善常染色体显性遗传性多囊肾病。
Cell Death Dis. 2021 Oct 14;12(10):947. doi: 10.1038/s41419-021-04248-9.

引用本文的文献

1
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Role in Cystogenesis and Novel Therapeutic Approaches.常染色体显性多囊肾病中的代谢重编程:在囊肿形成中的作用及新的治疗方法
Biomedicines. 2025 Jun 30;13(7):1596. doi: 10.3390/biomedicines13071596.
2
Ketone body β-hydroxybutyrate-mediated histone β-hydroxybutyrylation upregulates lipolysis and attenuates metabolic syndrome.酮体β-羟基丁酸介导的组蛋白β-羟基丁酰化上调脂肪分解并减轻代谢综合征。
Am J Physiol Cell Physiol. 2025 Sep 1;329(3):C726-C743. doi: 10.1152/ajpcell.00453.2025. Epub 2025 Jul 28.
3
Ketogenic diets in chronic kidney disease patients: a review for skeptics by skeptics.

本文引用的文献

1
A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease.β-羟丁酸和柠檬酸的联合使用可改善多囊肾病大鼠模型的疾病进展。
Am J Physiol Renal Physiol. 2024 Mar 1;326(3):F352-F368. doi: 10.1152/ajprenal.00205.2023. Epub 2023 Dec 14.
2
Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial.生酮饮食干预多囊肾病的可行性和影响:KETO-ADPKD-一项随机对照试验。
Cell Rep Med. 2023 Nov 21;4(11):101283. doi: 10.1016/j.xcrm.2023.101283. Epub 2023 Nov 7.
3
Reply to Najjar, R.S. Comment on "Dyńka et al. The Ketogenic Diet and Cardiovascular Diseases. 2023, , 3368".
慢性肾病患者的生酮饮食:怀疑者写给怀疑者的综述
J Nephrol. 2025 Apr 30. doi: 10.1007/s40620-025-02285-7.
4
Therapeutic Potential of Ketogenic Interventions for Autosomal-Dominant Polycystic Kidney Disease: A Systematic Review.生酮干预对常染色体显性多囊肾病的治疗潜力:一项系统评价
Nutrients. 2024 Dec 31;17(1):145. doi: 10.3390/nu17010145.
5
Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression.触发警告:现代饮食、生活方式和环境如何引发常染色体显性遗传性多囊肾病的进展。
Nutrients. 2024 Sep 27;16(19):3281. doi: 10.3390/nu16193281.
回复 Najjar, R.S. 对“Dyńka 等人的评论。生酮饮食与心血管疾病。2023,, 3368”。
Nutrients. 2023 Oct 10;15(20):4312. doi: 10.3390/nu15204312.
4
Cleavage fragments of the C-terminal tail of polycystin-1 are regulated by oxidative stress and induce mitochondrial dysfunction.多囊蛋白-1 C 端尾部的裂解片段受氧化应激调节,并诱导线粒体功能障碍。
J Biol Chem. 2023 Sep;299(9):105158. doi: 10.1016/j.jbc.2023.105158. Epub 2023 Aug 12.
5
Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects.常染色体显性多囊肾病的生酮饮食干预——一项回顾性病例系列研究:对可行性、安全性及效果的初步见解
Clin Kidney J. 2021 Sep 13;15(6):1079-1092. doi: 10.1093/ckj/sfab162. eCollection 2022 Jun.
6
Obacunone Retards Renal Cyst Development in Autosomal Dominant Polycystic Kidney Disease by Activating NRF2.奥巴库酮通过激活NRF2延缓常染色体显性多囊肾病中的肾囊肿发展。
Antioxidants (Basel). 2021 Dec 24;11(1):38. doi: 10.3390/antiox11010038.
7
Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.二甲双胍改善常染色体显性遗传性多囊肾病小鼠模型的相关疾病参数。
Am J Physiol Renal Physiol. 2022 Jan 1;322(1):F27-F41. doi: 10.1152/ajprenal.00298.2021. Epub 2021 Nov 22.
8
NLRP3 associated with chronic kidney disease progression after ischemia/reperfusion-induced acute kidney injury.NLRP3与缺血/再灌注诱导的急性肾损伤后慢性肾脏病进展相关。
Cell Death Discov. 2021 Oct 29;7(1):324. doi: 10.1038/s41420-021-00719-2.
9
The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults.酮体 β-羟丁酸减轻了肾小球足细胞对糖尿病损伤的衰老反应。
Kidney Int. 2021 Nov;100(5):1037-1053. doi: 10.1016/j.kint.2021.06.031. Epub 2021 Jul 8.
10
PLK2 protects retinal ganglion cells from oxidative stress by potentiating Nrf2 signaling via GSK-3β.PLK2 通过 GSK-3β 增强 Nrf2 信号来保护视网膜神经节细胞免受氧化应激。
J Biochem Mol Toxicol. 2021 Aug;35(8):e22815. doi: 10.1002/jbt.22815. Epub 2021 May 28.